P. Jeffrey Conn left a full professorship for a job in Big Pharma 11 years ago because he saw no path in academe to turn his novel idea for treating Parkinson's disease into an actual drug. Now he and a corps of scientists are closing in on a…
This content is available exclusively to Chronicle subscribers
Already a subscriber?
Log in now
Not a subscriber yet?
Subscribe now for instant access to this article and thousands of others, data tables, and interactive charts — all available exclusively for Chronicle subscribers. Plus your subscription includes weekly print or digital delivery of The Chronicle and The Review and the Chronicle iPad® Edition.Subscribe Today